Samsung Medical Center-Lymphoma Cohort Study

Not Applicable

Completed

• Conditions: Lymphoma
• Interventions: Drug: Chemotherapy with or without radiotherapy

• Registration Number: NCT00822731
• Lead Sponsor: Samsung Medical Center

Brief Summary

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Detailed Description

Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess following factors which amy probably affect the treatment outcome and the risk of treatment-related morbidity.

1. Biologic factors associated with the aggressiveness of lymphoma

* molecular markers in serum, cytogenetic markers

2. Factors associated with the risk of treatment-related morbidity

* comorbidity, nutrition status, performance status, quality of life at diagnosis

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-12-30
• Study First Submitted QC: 2009-01-12
• Study First Posted: 2009-01-14
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-22
• Last Update Posted: 2012-05-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 953

Inclusion Criteria

• Patients who were diagnosed as lymphoma
• Over 15 years old
• Patients who agreed the enrollment of study
• Informed consent for sampling

Exclusion Criteria

• Patients who do not want to join the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lymphoma	Chemotherapy with or without radiotherapy	patients diagnosed as lymphoma

Primary Outcome Measures

Name	Time	Method
all cause mortality	5 years

Secondary Outcome Measures

Name	Time	Method
Treatment response	after completion of primary therapy
Rate of occurrence of toxicity	2 years from the start of the 1st therapy
Treatment-related morbidity	within 60 days from the previous therapy

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of